Definium Therapeutics NASDAQ: DFTX reported positive top-line results from Panorama, its second Phas

DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, pavin

Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Bu

Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform a

Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 OD

Definium Therapeutics (DFTX) has seen a significant rise in its stock price following the announceme

Definium Therapeutics Inc. (NASDAQ:DFTX) on Monday released topline results from Panorama, its secon

Definium Therapeutics announced positive Phase 3 Panorama trial results for DT120 in generalized anx

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Definium Therapeutics (NASDAQ:DFTX

Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday&

Needham analyst Ami Fadia reiterates Definium Therapeutics (NASDAQ:DFTX) with a Buy and maintains

Study met primary and all key secondary efficacy endpoints; Panorama is the second positive Phase 3

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”),

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage c

RBC Capital analyst Brian Abrahams reiterates Definium Therapeutics (NASDAQ:DFTX) with a Outperfo

Emerge Phase 3 study podium poster to be featured in "Latest Discoveries & Emerging Trends i

https://www.bloomberg.com/news/articles/2026-09-08/fda-s-acting-drug-vaccine-regulators-tapped-for-p

The designation was supported by the significant unmet medical need in MDD and results from the Comp